Source Paper
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V <sub>1b</sub> receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
Guy Griebel, Jacques Simiand, Claudine Serradeil-Le Gal, Jean Wagnon, Marc Pascal et al.
Proceedings of the National Academy of Sciences • 2002
Chronic Mild Stress Model
Objective: To evaluate antidepressant-like and anxiolytic-like effects of SSR149415 in the chronic mild stress (CMS) model, measuring improvements in physical state, anxiety, despair, and coping behavior degradation produced by stress
This is a Chronic Mild Stress Model protocol using mouse as the model organism. The procedure involves 3 procedural steps, 1 materials. Extracted from a 2002 paper published in Proceedings of the National Academy of Sciences.
Model and subjects
mouse • Not specified • unknown • Not specified • Not specified
Study window
~5.6 week study window
Core workflow
Chronic Mild Stress Exposure • Drug Administration • Behavioral Assessment
Primary readouts
- Physical state degradation
- Anxiety levels
- Despair
- Loss of coping behavior
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Chronic Mild Stress Exposure
Mice exposed to chronic mild stress conditions over extended period
Note: CMS model used to induce depression-like symptoms including degradation of physical state, anxiety, despair, and loss of coping behavior
View evidence from paper
“in the CMS model in mice, repeated administration of SSR149415 (10 and 30 mg/kg, i.p.) for 39 days improved the degradation of the physical state, anxiety, despair, and the loss of coping behavior produced by stress”
Drug Administration
Repeated intraperitoneal administration of SSR149415 at specified doses
Note: Two dose levels tested: 10 mg/kg and 30 mg/kg via intraperitoneal injection
View evidence from paper
“repeated administration of SSR149415 (10 and 30 mg/kg, i.p.) for 39 days”
Behavioral Assessment
Evaluation of physical state degradation, anxiety levels, despair, and coping behavior changes
Note: Specific behavioral tests not detailed in provided text
View evidence from paper
“improved the degradation of the physical state, anxiety, despair, and the loss of coping behavior produced by stress”